3 unchanged sentences
In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.
−Removed: The following table summarizes the activity, by month, during the three months ended June 30, 2023:
+Added: The following table summarizes the activity, by month, during the three months ended September 30, 2023:
Period Total Number of
6 unchanged sentences
Purchased Under
−Removed: April 15,270 $ 1.96 $ 3,535,851
−Removed: May 32,427 1.73 3,479,730
−Removed: June 51,360 1.66 3,394,220
−Removed: 10.1 Amendment Number 3 to the Amended and Restated 2007 Long-Term Incentive Compensation Plan, incorporated herein by reference to Appendix A of the Company’s Schedule 14A (File No.:
−Removed: 001-33637) as filed with the SEC on March 15, 2023 and approved by the Company's shareholders on April 25, 2023.
+Added: July 29,132 $ 1.56 $ 3,348,711
+Added: August 53,518 1.68 3,258,885
+Added: September 33,914 1.94 3,192,982
+Added: Total 116,564
+Added: 10.1 Revolving Credit Loan Agreement, dated as of September 5, 2023, by and between Cumberland Pharmaceuticals Inc.
+Added: and Pinnacle Bank, incorporated herein by reference to Exhibit 10.1 of the Company’s Form 8-K (File No.:
+Added: 001-33637) as filed with the SEC on September 6, 2023.
31.1* Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
13 unchanged sentences
Cumberland Pharmaceuticals Inc.
−Removed: August 11, 2023 By:
+Added: November 13, 2023 By:
/s/ John Hamm
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.